S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ARTL Artelo Biosciences Inc

1.40

0.00 (0.00%)

Pre Market

Last Updated: 03:54:32

Delayed by 15 minutes

Form ARS - Annual Report to Security Holders

null

Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Artelo Biosciences Charts.

Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Artelo Biosciences Charts.

Artelo Biosciences Inc News

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
Monday 13 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Monday 9 December 2024 (2 months ago) • GlobeNewswire Inc.

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
Monday 18 November 2024 (3 months ago) • GlobeNewswire Inc.

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
Wednesday 13 November 2024 (3 months ago) • GlobeNewswire Inc.

Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Tuesday 12 November 2024 (3 months ago) • GlobeNewswire Inc.

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Friday 8 November 2024 (3 months ago) • Edgar (US Regulatory)

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
Tuesday 5 November 2024 (3 months ago) • GlobeNewswire Inc.

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
Wednesday 9 October 2024 (4 months ago) • GlobeNewswire Inc.

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Wednesday 4 September 2024 (5 months ago) • GlobeNewswire Inc.

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Tuesday 13 August 2024 (6 months ago) • GlobeNewswire Inc.

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
Monday 15 July 2024 (7 months ago) • GlobeNewswire Inc.

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
Wednesday 3 July 2024 (7 months ago) • GlobeNewswire Inc.

More Artelo Biosciences Inc News Articles

Adia Nutrition (PK)

Decentral Life (PK)

MineralRite (PK)

TransCode Therapeutics

RespireRx Pharmaceuticals (CE)

Virexit Technologies (PK)

Liquidmetal Technologies (QB)

Elite Pharmaceuticals (QB)

Enanta Pharmaceuticals

Rennova Health (CE)

Super Micro Computer

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions